ArticleEuropean journal of nutrition2025
Dietary quercetin intake is not associated with risk of metabolic dysfunction-associated steatotic liver disease in a general adult population.
Article in European journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction associated steatotic liver disease (MASLD) is the most common liver disease threatening public health. Quercetin is considered a promising candidate for treating and preventing MASLD, due to its antioxidant and anti-inflammatory properties. However, few studies have evaluated the association of daily quercetin intake with the risk of MASLD in the general population.
methodsThis prospective cohort study included 16,746 adults. Dietary quercetin intake was assessed using a validated food frequency questionnaire. Incident MASLD cases were ascertained annually by liver ultrasound and cardiometabolic risk factors. Multivariable Cox proportional-hazards models were used to evaluate the association between quercetin intake and the risk of MASLD.
resultsThe data from 16,746 participants, with an average follow-up time of approximately 3.47 years, were analyzed and 3,544 participants developed MASLD during follow-up. After Multivariable adjustment, the hazard ratio (95% confidence interval) for MASLD across increasing quartiles of quercetin intake was 1.00 (reference), 0.93 (0.85, 1.03), 1.01 (0.91, 1.12), and 1.04 (0.92, 1.17) (P for trend = 0.35). Similarly, the adjusted hazard ratio (95% confidence interval) for MASLD across increasing quartiles of energy density and per-unit-kilogram-body-weight intake was 1.00 (reference), 0.99 (0.89, 1.09), 0.98 (0.89, 1.09), 1.02 (0.92, 1.13) (P for trend = 0.77), and 1.00 (reference), 0.92 (0.84, 1.01), 0.92 (0.83, 1.02), 0.94 (0.83, 1.06) (P for trend = 0.29), respectively.
conclusionNo association was observed between dietary quercetin intake and the incidence of MASLD. The findings of this study need to be confirmed in other populations.
Indexed as
Identifiers
40694145What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.